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Objectives: Report a case of sirolimus induced granulomatous pneumonitis.
Background: Sirolimus is used in clinical transplantation as an immunosuppressive agent. Pulmonary
toxicity does occur, but only a few cases of sirolimus associated granulomatous interstitial pneumonitis
have been reported.
Methods: Case report and literature review.
Results: This 53-year-old woman with ESRD from polycystic kidney disease status post deceased donor
kidney transplantation presented with fever, progressive dyspnea, and hypoxia for two weeks. She had
been switched to sirolimus two months before admission. A CT scan of the chest revealed bilateral ill-
deﬁned patchy ground glass opacities. Extensive investigations were negative for infection. Video-
assisted thoracoscopic biopsy showed granulomatous interstitial pneumonitis. Her symptoms and
inﬁltrates resolved after sirolimus discontinuation and corticosteroid treatment.
Conclusions: Drugs induced pneumonitis should always be considered in transplant patients after
infectious or other etiologies have been excluded. Sirolimus can cause granulomatous inﬁltrates in the
lung possibly secondary to T-cell mediated hypersensitivity.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
The mammalian target of rapamycin inhibitor (mTORi) siroli-
mus was introduced into clinical transplantation in 1999.1 It is
frequently used either in the induction phase or for maintenance
immunosuppression to prevent acute and chronic rejection. Siro-
limus is often used to achieve adequate immunosuppression while
decreasing the dose and possible toxicity of primary agents, such as
calcineurin inhibitors. Dose related myelosuppression and hyper-
lipidemia are the most common side effects.1e3 Pulmonary toxicity
had been reported since 20004 and can cause interstitial pneu-
monitis, organizing pneumonia, and alveolar hemorrhage.1 To date,
there have been only a few case reports of granulomatous inter-
stitial pneumonitis associatedwith sirolimus.We describe a patient
with polycystic kidney disease with renal transplantation who was
switched to sirolimus two months before developing granuloma-
tous interstitial pneumonitis.
2. Case report
A 53-year-old woman, a non smoker with a past medical history
of hypertension and ESRD secondary to polycystic kidney disease,: þ1 806 743 3148.
ugent).
-NC-ND license.underwent deceased donor kidney transplantation in 2006. Her
medications were changed from tacrolimus and mycophenolic acid
to cyclosporine 25 mg twice a day and sirolimus 3 mg daily
approximately two months before admission. She presented with
fever, malaise, progressive shortness of breath, and cough with
minimal sputum for 2 weeks. She did not have any other symp-
toms. Physical examination showed stable vital signs, O2 saturation
96% on room air, and bilateral basilar ﬁne crackles. Lab tests showed
a Hb 8.4 g/dl, Hct 24%, MCV 77 fL, WBC 2.5 kU/l, neutrophils 55%,
lymphocytes 32%, eosinophils 0.1%, platelets 141 kU/l, sodium
136 mmol/l, potassium 4.2 mmol/l, chloride 102 mmol/l, bicar-
bonate 22 mmol/l, BUN 15 mg/dl, creatinine 0.9 mg/dl, and normal
liver enzyme. Her sirolimus level was high at 28.5 ng/dl. Urinalysis
did not show pyuria or hematuria. Chest radiograph revealed
bilateral thickened interstitial markings (Fig. 1). Computed
tomography scan of the chest without contrast showed ill-deﬁned
patchy ground glass opacities in both lungs (Fig. 2).
Cultures were obtained, and antibiotic drugs were started to
cover community-acquired pneumonia. The patient remained
tachypneic and desaturated. Broad spectrum antibiotic drugs were
continued with an antifungal drug (Mycamine) and trimethoprim
and sulfamethoxazole. BAL ﬂuid studies were negative for bacteria,
viruses, AFB, and fungi. BAL culture for mycobacteria was also
negative at eight weeks. The direct antigen for PCP was negative.
She underwent video-assisted thoracoscopic biopsy which showed
granulomas, interstitial ﬁbrosis, and focal organizing pneumonia
Fig. 1. Chest radiograph on admission showed bilateral increased interstitial markings.
Fig. 3. Wedge biopsy showed granulomas, interstitial ﬁbrosis, and focal organizing
pneumonia.
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The results were highly suspicious for sirolimus induced granulo-
matous interstitial pneumonitis, and sirolimus was stopped. The
patient was started on methylprednisolone 40 mg IV every 12 h.
She improved and was discharged on prednisone 30 mg/day,
cyclosporine 200 mg/day, and leﬂunomide 15 mg/day. She was
remarkably better two weeks later. Repeat computed tomography
scan of the chest one month later showed near complete resolution
of the previously seen interstitial lung disease, but some mild
interstitial lung disease remained with peripheral interlobular
septal thickening (Fig. 4).
3. Discussion
Sirolimus, initially known as rapamycin, is a macrolide antibiotic
derived from the actinomycete “Streptomyces hygroscopicus”.1 It isFig. 2. Computed tomography scan of the chest on admission showed bilateral patchy
ground glass opacities.also an immunosuppressive agent which inhibits T-lymphocyte
activation and proliferation and antibody production. It binds to FK-
binding protein-12 to form a complex which binds and inhibits the
activation of the mammalian target of rapamycin (mTOR). The
resulting inhibition of mTOR suppresses cytokine-driven T cell
proliferation resulting in inhibition of progression from the G1 to
the S phase of the cell cycle.1 It was introduced into clinical trans-
plantation and approved by the Food and Drug Administration in
1999. Since then it has been widely used as an effective immuno-
suppressive agent in induction or maintenance therapy. In phase III
clinical trials, sirolimus caused dose dependent hypercholesterol-
emia and hypertriglyceridemia which are the most frequent side
effects that probably result from the complex interference with
lipid metabolism. Sirolimus may also alter the insulin signaling
cascade and cause impaired glucose tolerance or overt post trans-
plant diabetes mellitus.2 Myelosuppression is another dose related
sirolimus side effect. Sirolimus also has adverse kidney effects,
causing acute renal toxicity by increasing the apoptosis of tubularFig. 4. Computed tomography scan of the chest performed one month after discharge
showed resolution of ground glass opacities.
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recovery of renal function after ischemia-reperfusion injury.
Proteinuria can be found in up to 30% of patients. Severe proteinuria
and high dose sirolimus induced focal segmental glomerulo-
sclerosis have been reported. Proteinuria is usually controlled by
initiating angiotensin-converting enzyme inhibitors or angiotensin
II receptor antagonists and reducing sirolimus blood level to below
10e12 ng/ml.2 Gastrointestinal side effects include mouth ulcers
which are common and dose related, abdominal pain, nausea,
constipation, diarrhea, hepatotoxicity, hepatic necrosis, and hepatic
artery thrombosis. Other potential side effects include eyelid
edema or peripheral edema that often reverses with dose reduc-
tion, poor wound healing from antiproliferative activity, arthralgia
which usually resolves with dose reduction, impaired fertility, and
the development of lymphoceles from antilymphoangogenic
effects.2
To date sirolimus has been associated with a rare but serious
pulmonary toxicity. The mechanism of sirolimus induced intersti-
tial pneumonitis is still unclear. A cell-medicated autoimmune
response may have a role when cryptic pulmonary antigens are
exposed, and this causes lymphocytic alveolitis and interstitial
pneumonitis. T-cell mediated, delayed type hypersensitivity may
be another pathogenic mechanism.3 Histologic features in our case
shows granulomatous interstitial inﬂammation which suggests
a role of T-cell medicated hypersensitivity reaction to circulating
antigens or immune complexes in the lungs. T cell lymphocytes
produce IL-2 and IFN-gamma which stimulate alveolar macro-
phages and also produce TNF- alpha and IL-1. ActivatedTable 1
Review of sirolimus induced granulomatous interstitial pneumonitis.
Source Number of
cases/type of
transplant
Age/sex Symptoms and
duration of
sirolimus exposure
Sirolimus
dose/level
Morelon
et al.3 2001
8/kidney 4 male
4 female
Mean
age 56
7/8 had pulmonary
symptoms
1/8 asymptomatic
Not available
Dose not a
Level 15e3
Avitzur
et al.10 2003
1/liver 8/female Fatigue, decreased
appetite
9 months of sirolimus
0.12e0.18
Level 5 ng/
Seethamraju
et al.11 2003
4/lung Not
available
Not available Not availab
Howard
et al.12 2006
1/liver 73/female Fever, dyspnea,
nonproductive cough
2 weeks of sirolimus
Dose not a
Level 6.1e
Hamour
et al.14 2006
1/heart 59/male Fever, fatigue, dyspnea
2 months of sirolimus
1 mg/day
Level 8.8 n
Robert
et al.13 2007
4/liver 53/male Dyspnea and cough
3 months of sirolimus
Dose not a
Median lev
Our case 1/kidney 53/female Fever, dyspnea,
productive cough
2 months of sirolimus
3 mg/day
Level 28.5macrophages secrete several chemokines, such as monocyte che-
moattractant protein-1 (MCP-1) and macrophage inﬂammatory
protein 1 alpha (MIP-1a), and transform into epitheloid cells and
multinucleated cells contributing to cellular inﬁltration and gran-
uloma formation.5
These patients usually present with fever, progressive dyspnea,
dry or productive cough, and occasional hemoptysis. The common
radiological ﬁndings are bilateral patchy, interstitial opacities.
Consolidation or nodular opacities are less commonly seen. BAL
lymphocytosis is usually associatedwith drug induced pneumonitis.
The histopathological features from biopsies include organizing
pneumonia, interstitial pneumonitis, focal ﬁbrosis, non-necrotizing
macrophagocytic granulomas, and pulmonary hemorrhage.6,7 Risk
factors of sirolimus induced pulmonary pneumonitis are not
completely understood. Previous studies have reported that male
gender, high dose sirolimus, and exposure to sirolimus after toxicity
to other drugsmay increase the risk of pulmonary toxicity. However,
patients with therapeutic sirolimus levels can also develop pulmo-
nary toxicity.8,9
Granulomatous interstitial pneumonitis was reported in 2001 in
two adults who were S/P renal transplantation. One of the patients
was initially treated with anti-tuberculosis medication for two
months and improved after sirolimus was withdrawal.3 In 2003,
Avitzur et al.10 described a case of sirolimus induced granulomatous
interstitial pneumonitis in a child following liver transplantation.
The child had several concurrent pathological processes: diffuse
pneumonitis with alveolar proteinosis, two well-formed granu-
lomas with multinucleated giant cells, and mucosal lymphoidRadiograph Method of tissue
obtained/Histology
Outcome
vailable
0 ng/ml
Bilateral
asymmetrical
inﬁltrates
in all patients
Only 2/8 underwent
transbronchial biopsy;
Organizing pneumonia,
interstitial lymphocytic
inﬁltrate and nonnecrotizing
macrophagic granuloma
All
patients
alive
mg/kg/day
ml
Multiple
parenchymal
nodular
opacities
Open lung biopsy;
Diffuse pneumonitis, alveolar
proteinosis, granulomatous
interstitial pneumonitis, PTLD
Alive
le Not available Transbronchial biopsy;
2 patients: granulomatous
interstitial pneumonitis
2 patients: pulmonary
alveolar proteinosis
Alive
vailable
13.1 ng/ml
Bilateral pleural
effusion,
consolidation
in the left
lower lobe
Transbronchial biopsy;
Granulomatous interstitial
pneumonitis, noncaseating
granuloma, organizing
pneumonia
Alive
g/ml
Ground glass
opaciﬁcation
and patchy
consolidation
in the left
lower lobe
Transbronchial biopsy
Lymphocytic interstitial
pneumonitis with
non-caseating granulomas
Alive
vailable
el 9.7 ng/ml
Patchy ground
glass change
in the upper and
lower lobes,
bilateral pleural
effusions
Transbronchial biopsy;
Interstitial non-caseating
granuloma, granulomatous
pneumonitis
Alive
ng/ml
Bilateral interstitial
inﬁltrates
Open lung biopsy;
Granulomatous interstitial
pneumonitis, focal
organizing pneumonia
Alive
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EBV encoded RNA stain and positive CD-20 stain consistent with
EBV positive PTLD of the benign lymphoid hyperplasia subtype.
Sirolimus was discontinued, and she was treated with ganciclovir
and anti CD-20 monoclonal antibody (Rituximab). Seethamraju
et al.11 also reported two cases of granulomatous interstitial
pneumonia associated with sirolimus toxicity in lung transplant
patients. Howard et al.12 described an orthotopic liver transplant
case who developed respiratory symptoms after two weeks of
sirolimus; transbronchial biopsy showed granulomatous interstitial
pneumonitis and organizing pneumonia. The patient’s symptoms
improved within a few days after sirolimus was replaced with
tacrolimus, and the chest radiograph improved during three
months later. Sirolimus is more widely used later in liver trans-
plantation. Robert et al. reported a case series of four liver trans-
plant patients from the center in UK who were switched to
sirolimus therapy prior to their respiratory symptoms.12,13 Two of
them had granulomatous interstitial pneumonitis from lung biopsy.
The other two patients had diffuse alveolar damage and mild
interstitial pneumonitis. Sirolimus is also used after heart trans-
plantation, and Hamour reported a case with granulomatous
interstitial pneumonitis after two months of low dose sirolimus in
a 53-year-old man with a heart transplantation for ischemic
cardiomyopathy14 (Table 1).
Granulomatous lung lesion can be secondary to infectious cau-
ses, such as tuberculosis, non-tuberculous mycobacterium, histo-
plasmosis, cryptococcosis, blastomycosis, and coccidioidomycosis.
Non-infectious granulomatous diseases like sarcoidosis, ber-
ylliosis, Wegener’s granulomatosis, Churg-Strauss disease, and
even foreign body granulomatous reaction need to be considered in
the differential diagnosis. The patient’s immune status is important
in evaluating granulomatous lung lesions so extensive investigation
should be started in these transplant patients because sirolimus
associated pulmonary toxicity should be a diagnosis of exclusion.
Morelon et al.3 developed the following diagnosis criteria for
sirolimus induced lung disease:Table 2
Naranjo scale.
1. Are there previous conclusive reports on this reaction?
Yes (þ1) No (0) Do not know or not done (0)
þ1
2. Did the adverse event appear after the suspected
drug was given?
Yes (þ2) No (1) Do not know or not done (0)
þ2
3. Did the adverse reaction improve when the drug was
discontinued or a speciﬁc antagonist was given?
Yes (þ1) No (0) Do not know or not done (0)
þ1
4. Did the adverse reaction appear when the drug was
readministered?
Yes (þ2) No (1) Do not know or not done (0)
0
5. Are there alternative causes that could have caused
the reaction?
Yes (1) No (þ2) Do not know or not done (0)
0
6. Did the reaction reappear when a placebo was given?
Yes (1) No (þ1) Do not know or not done (0)
0
7. Was the drug detected in any body ﬂuid in toxic
concentrations?
Yes (þ1) No (0) Do not know or not done (0)
þ1
8. Was the reaction more severe when the dose was
increased, or less severe when the dose was decreased?
Yes (þ1) No (0) Do not know or not done (0)
0
9. Did the patient have a similar reaction to the same or
similar drugs in any previous exposure?
Yes (þ1) No (0) Do not know or not done (0)
0
10. Was the adverse event conﬁrmed by any objective evidence?
Yes (þ1) No (0) Do not know or not done (0)
þ1
Naranjo score 6 probable adverse drug reaction.
Scoring:>9e deﬁnite ADR; 5e8e probable ADR; 1e4e possible ADR; 0e doubtful
ADR.1. Exposure to sirolimus preceding the onset of pulmonary
symptoms.
2. Exclusion of infection or alternative pulmonary disease,
including toxicity due to other drugs, such as azathioprine,
beta-blockers, ﬁbrates, sulfamethoxazole and trimethoprim.
3. Resolution after sirolimus discontinuation.
4. Lymphocytic alveolar cellular proﬁle and pathological ﬁndings,
although nonspeciﬁc, consistent with drug-induced pulmonary
toxicity.
In the casewedescribe thepatientwas switched to sirolimus two
months before the onset of respiratory symptoms. Cultures
and serologies did not show evidence of infection, and the patient
did not improve after empiric antibiotic and antifungal therapy.
The resolution of symptoms and radiographic ﬁndings after siroli-
mus discontinuation supported the diagnosis of sirolimus induced
granulomatous interstitial pneumonitis with Naranjo score of 6
(Table 2)whichmeans probable adverse drug reaction. Although the
beneﬁt of steroid has not been clearly documented, our patient
received methylprednisone and was discharged on prednisone.
4. Conclusion
We describe a patient with a renal transplant for polycystic
kidney disease who developed respiratory symptoms and inter-
stitial inﬁltrates after the addition of sirolimus. After opportunistic
infection and other autoimmune related pulmonary conditions are
excluded, drug-induced pulmonary hypersensitivity should be in
the differential diagnosis in these patients. Discontinuation of the
culprit drug can be life saving.
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